Abiopharma

Fractyl Health Announces Closing of $23 Million Underwritten Public Offering Including Full Exercise of Underwriter’s Option to Purchase Additional Shares

RxSight, Inc. Reports Second Quarter 2025 Financial Results

Sight Sciences Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance

Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Ventyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Progress

New Form 6-K - Ascendis Pharma A/S Filed: 2025-08-07 AccNo: 0001193125-25-175420 Size: 146 KB

New Form SCHEDULE 13G/A - Phio Pharmaceuticals Corp. Filed: 2025-08-07 AccNo: 0001641172-25-022581 Size: 7 KB

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Kura Oncology Reports Second Quarter 2025 Financial Results

iSpecimen to Establish $200M Corporate Treasury Built Around Solana Cryptocurrency with BlockArrow

10x Genomics - 10x Genomics Reports Second Quarter 2025 Financial Results

Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Astrana Health, Inc. Reports Second Quarter 2025 Results

New Form 3 - Twist Bioscience Corp Filed: 2025-08-07 AccNo: 0001214659-25-011687 Size: 8 KB

New Form 4 - Twist Bioscience Corp Filed: 2025-08-07 AccNo: 0001214659-25-011688 Size: 4 KB